ReviewNanomedicine (London, England)2011
Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.
Review in Nanomedicine (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Improved Anticancer Properties of Silver Nanoparticles by Albumin Coating in Prostate Cancer Cell Lines: An In Vitro Study.Pharmaceutics · 2026Article
- Elacridar Reverses P-gp-Mediated Drug Resistance in Ovarian Cancer Cells in 2D and 3D Culture Models.International journal of molecular sciences · 2025Article
- Effect ofInternational journal of molecular sciences · 2022Article
- Recent Developments in the Study of the Microenvironment of Cancer and Drug Delivery.Current drug metabolism · 2022Article
- Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells.Acta pharmacologica Sinica · 2021Article
- Raltitrexed-Modified Gold and Silver Nanoparticles for Targeted Cancer Therapy: Cytotoxicity Behavior In Vitro on A549 and HCT-116 Human Cancer Cells.Materials (Basel, Switzerland) · 2021Article
- Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems.Pharmaceutics · 2021Review
- Target Site Delivery and Residence of Nanomedicines: Application of Quantitative Systems Pharmacology.Pharmacological reviews · 2019Review
- Systemic Bioequivalence Is Unlikely to Equal Target Site Bioequivalence for Nanotechnology Oncologic Products.The AAPS journal · 2019Review
- Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery.Theranostics · 2019Review
- Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.Nanomedicine (London, England) · 2017Review
- Anti-cancerous effect of albumin coated silver nanoparticles on MDA-MB 231 human breast cancer cell line.Scientific reports · 2017Article
- Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo.Biomaterials · 2017Article
- Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Drug design, development and therapy · 2017Review
- PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.Advanced drug delivery reviews · 2016Review
- Evaluation of uptake and distribution of gold nanoparticles in solid tumors.European physical journal plus · 2015Article
- Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.The AAPS journal · 2015Review
- Detection of Phosphatidylcholine-Coated Gold Nanoparticles in Orthotopic Pancreatic Adenocarcinoma using Hyperspectral Imaging.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Effectiveness of nanomedicines in cancer therapy is limited in part by inadequate delivery and transport in tumor interstitium. This article reviews the experimental approaches to improve nanomedicine delivery and transport in solid tumors. These approaches include tumor vasculature normalization, interstitial fluid pressure modulation, enzymatic extracellular matrix degradation, and apoptosis-inducing tumor priming technology. We advocate the latter approach due to its ease and practicality (accomplished with standard-of-care chemotherapy, such as paclitaxel) and tumor selectivity. Examples of applying tumor priming to deliver nanomedicines and to design drug/RNAi-loaded carriers are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.